Published in Ann Oncol on July 05, 2012
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res (2015) 0.87
Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep (2015) 0.78
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol (2016) 0.78
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs (2015) 0.76
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol (2015) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst (2003) 7.06
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol (2009) 5.11
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol (2008) 4.27
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol (2002) 4.15
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol (2005) 2.88
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 2.36
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 2.27
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27
Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol (2008) 2.13
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res (2000) 2.12
High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer (2000) 2.08
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol (2008) 2.02
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol (2010) 1.93
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer (2000) 1.56
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology (2009) 1.43
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg (2008) 1.24
Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer (2001) 1.21
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm (2001) 1.21
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas (2008) 1.15
Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer (2009) 1.09
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol (2009) 1.07
Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med (2006) 1.04
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas (2003) 1.02
Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett (2003) 0.99
Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res (1998) 0.99
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets (2006) 0.97
Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol (2000) 0.96
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer (2009) 0.93
Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery (2003) 0.91
[Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)]. Gan To Kagaku Ryoho (2003) 0.90
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs (1999) 0.86
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia (2011) 0.82
Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res (2002) 0.80
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol (2008) 0.78
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging (1991) 11.44
Safety and efficacy of laparoscopic cholecystectomy. A prospective analysis of 100 initial patients. Ann Surg (1991) 8.49
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet (2000) 8.33
Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature (2000) 7.37
Sequence complexity of disordered protein. Proteins (2001) 6.97
Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell (2000) 6.81
Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol (2001) 5.17
Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell (2001) 4.92
Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J (2009) 4.54
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell (1993) 4.30
Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol (2001) 4.25
GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature (1998) 4.09
Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun (1992) 4.02
Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry (1997) 3.90
Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J (1999) 3.67
Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature (1995) 3.58
Interaction of NPR1 with basic leucine zipper protein transcription factors that bind sequences required for salicylic acid induction of the PR-1 gene. Proc Natl Acad Sci U S A (1999) 3.56
CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep (2001) 3.55
Ordered restriction maps of Saccharomyces cerevisiae chromosomes constructed by optical mapping. Science (1993) 3.54
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science (2001) 3.23
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol (2001) 3.20
Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice. Gastroenterology (1996) 3.15
Age-related changes in the collagen network and toughness of bone. Bone (2002) 3.13
Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci (1999) 3.10
Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of helicobacter-induced carcinogenesis. Infect Immun (1996) 3.09
Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer (2004) 2.97
A randomized, controlled effectiveness trial of an AIDS prevention program for low-income African-American youths. Arch Pediatr Adolesc Med (1996) 2.95
Effectiveness of laser therapy and topical desensitising agents in treating dentine hypersensitivity: a systematic review. J Oral Rehabil (2011) 2.91
Dedifferentiation of epidermal cells to stem cells in vivo. Lancet (2001) 2.90
A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell (1993) 2.80
An extreme distortion of the Van Allen belt arising from the 'Hallowe'en' solar storm in 2003. Nature (2004) 2.76
Positional cloning of the mouse saccharin preference (Sac) locus. Chem Senses (2001) 2.75
Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med (2000) 2.75
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Diffusion tensor imaging of acute mild traumatic brain injury in adolescents. Neurology (2008) 2.67
Adhesion formation after previous caesarean section-a meta-analysis and systematic review. BJOG (2010) 2.66
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58
Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics (1992) 2.55
Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med (1995) 2.52
Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Nature (1999) 2.50
Computed tomography imaging features and classification of isolated dissection of the superior mesenteric artery. Eur J Vasc Endovasc Surg (2013) 2.50
Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med (1993) 2.49
Development of a culturally, theoretically and developmentally based survey instrument for assessing risk behaviors among African-American early adolescents living in urban low-income neighborhoods. AIDS Educ Prev (1995) 2.48
Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect Immun (1996) 2.47
IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem (1999) 2.43
Characterization of the two small subunits of Saccharomyces cerevisiae DNA polymerase delta. J Biol Chem (1998) 2.42
Generation of broad-spectrum disease resistance by overexpression of an essential regulatory gene in systemic acquired resistance. Proc Natl Acad Sci U S A (1998) 2.40
Effectiveness of the 40 adolescent AIDS-risk reduction interventions: a quantitative review. J Adolesc Health (1997) 2.37
MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol (2001) 2.33
Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer (2001) 2.32
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
LAI inversion algorithm based on directional reflectance kernels. J Environ Manage (2006) 2.31
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med (1995) 2.24
Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem (1999) 2.23
Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo. Magn Reson Med (1999) 2.21
Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem (1994) 2.20
An anchoring theory of lightness perception. Psychol Rev (1999) 2.20
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18
Surveillance of the first case of human avian influenza A (H7N9) virus in Beijing, China. Infection (2013) 2.18
A long-lived relativistic electron storage ring embedded in Earth's outer Van Allen belt. Science (2013) 2.16
Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci U S A (1997) 2.15
Processing of branched DNA intermediates by a complex of human FEN-1 and PCNA. Nucleic Acids Res (1996) 2.13
Parental underestimates of adolescent risk behavior: a randomized, controlled trial of a parental monitoring intervention. J Adolesc Health (2000) 2.12
Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity (2010) 2.08
PEX19 binds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis. J Cell Biol (2000) 2.07
Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet (1994) 2.06
Parental influence on adolescent sexual behavior in high-poverty settings. Arch Pediatr Adolesc Med (1999) 2.06
Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol (1994) 2.06
Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology (2007) 2.05
Formation of the compact confomer of kinesin requires a COOH-terminal heavy chain domain and inhibits microtubule-stimulated ATPase activity. J Biol Chem (1999) 2.05
Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome. J Eur Acad Dermatol Venereol (2012) 2.03
Polymorphisms in the taste receptor gene (Tas1r3) region are associated with saccharin preference in 30 mouse strains. J Neurosci (2004) 2.03
The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell (1997) 2.02
Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis. Scand J Rheumatol (2013) 2.02
The nation-wide Swedish family-cancer database--updated structure and familial rates. Acta Oncol (2001) 1.98
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med (2000) 1.96
Molecular identification of the ryanodine receptor pore-forming segment. J Biol Chem (1999) 1.95
Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax (1999) 1.94
Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol (2001) 1.93
Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res (1999) 1.92
NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem (1995) 1.91
Complications of splenectomy. Etiology, prevention, and management. Surg Clin North Am (1983) 1.88
The functional and molecular characterisation of human embryonic stem cell-derived insulin-positive cells compared with adult pancreatic beta cells. Diabetologia (2011) 1.87
The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin Exp Allergy (1997) 1.87
Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J (1996) 1.85
Efficient asymmetric synthesis of biologically important tryptophan analogues via a palladium-mediated heteroannulation reaction. J Org Chem (2001) 1.85
Pim kinase-dependent inhibition of c-Myc degradation. Oncogene (2008) 1.85
Complications of laparoscopic cholecystectomy. Surgery (1991) 1.85
Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China with high lung cancer mortality associated with exposure to unvented coal smoke. Carcinogenesis (1995) 1.82
Response to environmental flows in the lower Tarim River, Xinjiang, China: ground water. J Environ Manage (2006) 1.81
Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem (2001) 1.80
Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell (2000) 1.79
Preoperative percutaneous transhepatic biliary decompression lowers operative morbidity in patients with obstructive jaundice. Am J Surg (1981) 1.78
Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene (2008) 1.76